谈春江,杜娟
TAN Chunjiang,DU Juan

• 1:贵阳医学院附院呼吸内科

摘要(Abstract)：

目的:探讨慢性阻塞性肺疾病(COPD)稳定期基质金属蛋白酶-9(MMP-9)和γ-干扰素(IFN-γ)与患者肺功能受损严重程度的相关性。方法:选取COPD稳定期患者80例,按用力肺活量(FVC)、1 s钟用力呼气容积(FEV1)、FEV1/FVC的临床严重度分级标准分为I级、II级、III级及IV级组4组,同时选取25例健康对照者(健康对照组),比较各组FEV1占预计值的百分比(FEV1%pred)与FEV1/FVC水平,并检测IFN-γ、MMP-9水平,分析IFN-γ、MMP-9与肺功能受损严重程度的相关性。结果:COPD稳定期各组患者血清IFN-γ、MMP-9浓度较健康对照组升高,差异有统计学意义(P<0.05);COPD稳定期,随着肺功能的降低,患者血清中MMP-9、IFN-γ含量升高,MMP-9、IFN-γ含量呈正相关(r=0.868,P<0.05);COPD稳定期患者血清中MMP-9与肺功能受损严重程度(FEV1占预计值的百分比)呈负相关,(r=-0.849,P<0.05);COPD稳定期患者血清中IFN-γ与肺功能受损严重程度(FEV1占预计值的百分比)呈负相关,(r=-0.896,P<0.05)。结论:COPD稳定期患者血清MMP-9、IFN-γ可能参与了COPD慢性炎症反应引起肺损伤的发病机制。
Objective: To investigate the relevance between MMP-9 and IFN-γ together with the severity of pulmonary function in stable chronic obstructive pulmonary disease( COPD). Methods:Eighty patients with chronic obstructive pulmonary disease were divided into 4 groups according to FVC,1 min FEV1,FEV1 / FVC clinical severity classification as group Ⅰ,group Ⅱ,group Ⅲ and group Ⅳ,25 health people served as control group. Comparing the levels of FEV1% pred and FEV1 /FVC of each group,testing IFN-γ,MMP-9 levels,analyzing relevance between IFN-γ,MMP-9 and severity of pulmonary function. Results: IFN-γ and MMP-9 in serum were higher than control group,differences were statistically significant( P < 0. 05). In stable COPD,with the decrease of pulmonary function,IFN-γ,MMP-9 levels were increased,IFN-γlevel was positively correlated with MMP-9 level( r = 0. 868,P < 0. 05),MMP-9 and IFN-γ levels in serum were negatively correlated with the severity of pulmonary function( r =- 0. 849,P < 0. 05; r = 0. 868,P < 0. 05). Conclusions: MMP-9 and IFN-γ may participate in COPD chronic inflammation.

关键词(KeyWords)： 慢性阻塞性肺疾病;基质金属蛋白酶-9;γ-干扰素;肺功能
chronic obstructive pulmonary disease;matrix metalloproteinase-9;interferon-gamma;pulmonary function

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 谈春江,杜娟
TAN Chunjiang,DU Juan

DOI: 10.19367/j.cnki.1000-2707.2015.02.013

参考文献(References)：

• [1]Rabe KF,Wedzicha JA.Controversies in treatment of chronic obstructive pulmonary disease[J].Lancet,2011(9795):1038-1047.
• [2]中华医学会呼吸病学分会.慢性阻塞性肺疾病诊治指南[J].中华结核和呼吸杂志,2013(4):255-264.
• [3]Brusselle GG,Joos GF,Bracke KR.New insights into the immunology of chronic obstructive pulmonary disease[J].Lancet,2011(9795):1015-1026.
• [4]Martinez-Lemus LA,Galianes EL.Matrix metalloproteinases and small artery remodeling[J].Drug Discovery Today:Disease Models,2011(8):21-28.
• [5]van Eeden SF,Hogg JC.Chronic obstructive pulmonary disease:do regional differences in tissue inflammation matter[J].Respiration,2011(5):359-361.
• [6]Hur M,Moon HW,Yun YM,et al.Comparison of diagnostic utility between procalcitonin and C-reactive protein for the patients with blood culture positive sepsis[J].Korean J Lab Med,2009(6):529-535.
• [7]高风英,王星海.慢性阻塞性肺疾病稳定期慢性肺损伤的机制研究[J].实用心脑肺血管病,2012(10):1595-1597.

文章评论(Comment)：